Please use this identifier to cite or link to this item:
Title: Individualized Therapy with Ranibizumab in Wet Age-Related Macular Degeneration.
Authors: García-Layana, Alfredo
Figueroa, Marta S
Arias, Luis
Araiz, Javier
Ruiz-Moreno, José María
García-Arumí, José
Gómez-Ulla, Francisco
López-Gálvez, María Isabel
Cabrera-López, Francisco
García-Campos, José Manuel
Monés, Jordi
Cervera, Enrique
Armadá, Félix
Gallego-Pinazo, Roberto
metadata.dc.contributor.authoraffiliation: [García-Layana,A] Clínica Universitaria de Navarra, Pamplona, Spain. [García-Layana,A; Figueroa,MS; Arias,L; Araiz,J; Ruiz-Moreno,MJ; García-Arumí,J; Gómez-Ulla,F; López-Gálvez,MI; Cabrera-López,F; García-Campos,JM; Monés,J; Cervera,E; Armadá,F; Gallego-Pinazo,R] Sociedad Española de Retina y Vítreo, Santiago de Compostela, Spain. [García-Layana,A; Figueroa,MS; Arias,L; Araiz,J; Ruiz-Moreno,MJ; García-Arumí,J; Gómez-Ulla,F; López-Gálvez,MI] RETICS OFTARED (RD12/0034) “Prevention Early Detection and Treatment of the Prevalent Degenerative and Chronic Ocular Pathology”, Institute of Health Carlos III, Madrid, Spain. [Figueroa, MS] Hospital Universitario Ramón y Cajal, Madrid, Spain. [Figueroa,MS] Vissum Madrid, Spain. [Arias,L] Bellvitge Hospital, Barcelona, Spain. [Araiz, J] Hospital San Eloy, Baracaldo, Spain. [Ruiz-Moreno,MJ] Hospital Universitario de Albacete, Spain. [García-Arumí,J] Hospital Valle de Hebrón, Barcelona, Spain. [Gómez-Ulla,F] Instituto Oftalmológico Gómez Ulla, Santiago de Compostela, Spain. [López-Gálvez,MI] Hospital Clínico Universitario de Valladolid, Spain. [Cabrera-López,F] Complejo Hospitalario Universitario Insular Materno Infantil, Las Palmas de Gran Canaria, Spain. [García-Campos,JM] Hospital Universitario Virgen de la Victoria, Málaga, Spain. [Monés,J] Instituto Macula & Retina, Barcelona, Spain. [Cervera, E] Hospital General de Valencia, Spain. [Armadá,F] Hospital La Paz, Madrid, Spain. [Gallego-Pinazo,R] Hospital La Fe, Valencia, Spain.
Keywords: Anticuerpos monoclonales humanizados;Degeneración macular;Factor A de crecimiento endotelial vascular;Agudeza visual;Degeneración macular húmeda;Protocolos clínicos;Recurrencia;Humanos
metadata.dc.subject.mesh: Medical Subject Headings::Chemicals and Drugs::Amino Acids, Peptides, and Proteins::Proteins::Blood Proteins::Immunoproteins::Immunoglobulins::Antibodies::Antibodies, Monoclonal::Antibodies, Monoclonal, Humanized
Medical Subject Headings::Diseases::Eye Diseases::Retinal Diseases::Retinal Degeneration::Macular Degeneration
Medical Subject Headings::Chemicals and Drugs::Amino Acids, Peptides, and Proteins::Peptides::Intercellular Signaling Peptides and Proteins::Angiogenic Proteins::Vascular Endothelial Growth Factors::Vascular Endothelial Growth Factor A
Medical Subject Headings::Analytical, Diagnostic and Therapeutic Techniques and Equipment::Diagnosis::Diagnostic Techniques and Procedures::Diagnostic Techniques, Ophthalmological::Vision Tests::Visual Acuity
Medical Subject Headings::Diseases::Eye Diseases::Retinal Diseases::Retinal Degeneration::Macular Degeneration::Wet Macular Degeneration
Medical Subject Headings::Health Care::Health Care Quality, Access, and Evaluation::Quality of Health Care::Health Care Evaluation Mechanisms::Epidemiologic Study Characteristics as Topic::Clinical Protocols
Medical Subject Headings::Diseases::Pathological Conditions, Signs and Symptoms::Pathologic Processes::Disease Attributes::Recurrence
Medical Subject Headings::Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans
Issue Date: Nov-2015
Publisher: Hindawi Publishing Corporation
Citation: García-Layana A, Figueroa MS, Arias L, Araiz J, Ruiz-Moreno JM, García-Arumí J, et al. Individualized Therapy with Ranibizumab in Wet Age-Related Macular Degeneration. J Ophthalmol; 2015:412903
Abstract: Individualized treatment regimens may reduce patient burden with satisfactory patient outcomes in neovascular age-related macular degeneration. Intravitreal anti-VEGF drugs are the current gold standard. Fixed monthly injections offer the best visual outcome but this regimen is not commonly followed outside clinical trials. A PRN regimen requires monthly visits where the patient is treated in the presence of signs of lesion activity. Therefore, an early detection of reactivation of the disease with immediate retreatment is crucial to prevent visual acuity loss. Several trials suggest that "treat and extend" and other proactive regimens provide a reasonable approach. The rationale of the proactive regimens is to perform treatment anticipating relapses or recurrences and therefore avoid drops in vision while individualizing patient followup. Treat and extend study results in significant direct medical cost savings from fewer treatments and office visits compared to monthly treatment. Current data suggest that, for one year, PRN is less expensive, but treat and extend regimen would likely be less expensive for subsequent years. Once a patient is not a candidate to continue with treatment, he/she should be sent to an outpatient unit with adequate resources to follow nAMD patients in order to reduce the burden of specialized ophthalmologist services.
Description: Journal Article; Review;
metadata.dc.identifier.doi: 10.1155/2015/412903
ISSN: 2090-004X (Print)
2090-0058 (Online)
Appears in Collections:01- Artículos - Hospital Virgen de la Victoria

Files in This Item:
File Description SizeFormat 
Garcia_Individualized.pdfRevisión publicada1,27 MBAdobe PDFView/Open

This item is protected by original copyright

This item is licensed under a Creative Commons License Creative Commons